Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Withdrawn before enrolling · Phase 1

Conditions studied: Melanoma

In brief

The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable

Key facts

Study ID

NCT00803374

Run by

Bristol-Myers Squibb

People needed

0

Starts

2010-11-01

Expected to finish

2013-01-01

Last updated by the study team

2011-11-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed malignant melanoma
• Stage III (unresectable) or Stage IV disease which may have been treated with up to one prior cytotoxic chemotherapy and/or up to 3 other therapeutic regimens
• Willing to undergo up to 3 biopsies of an accessible lesion

You may not qualify if…

• Active/symptomatic brain metastases
• Primary ocular melanoma or primary tumor of unknown origin
• Concurrent autoimmune disease
• Previous treatment with a CD137 agonist or CTLA-4 inhibitor

Where it is running

• Local Institution — Los Angeles, California, United States
• Local Institution — New Haven, Connecticut, United States
• Local Institution — Tampa, Florida, United States
• Local Institution — Boston, Massachusetts, United States
• Local Institution — Boston, Massachusetts, United States
• Local Institution — Boston, Massachusetts, United States
• Local Institution — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.